Humana shares rise after insurer says medical costs came in lower than expected

Humana shares rise after insurer says medical costs came in lower than expected


A Humana office in Louisville, Kentucky, July 31, 2023.

Jon Cherry | Bloomberg | Getty Images

Humana shares rose Wednesday after the health insurer said medical costs came in lower than expected during its second-quarter earnings report.

The results ease investor concerns two months after Humana and rival UnitedHealth Group warned that a surge in demand for nonurgent surgeries and outpatient services among seniors was driving up claims. 

Both companies — the two biggest providers of Medicare Advantage plans for people ages 65 and above — have now suggested the uptick may be abating. 

Humana reported a medical loss ratio, the percentage of premiums it spends on medical care, of 86.3% for the second quarter. Analysts had estimated that ratio would be 86.5%, according to Refinitiv data.

Humana highlighted a “stabilizing Medicare Advantage utilization environment” based on the most recent claims activity, without elaborating.

The company said in June it expected its second-quarter medical loss ratio to be toward the top range of its full-year outlook of 86.3% to 87.3%. Humana reiterated that full-year guidance Wednesday.

Humana’s stock rose 5% in morning trading Wednesday. Shares are down about 5% for the year after the broader health-care sector took a beating in June, putting the company’s market value at around $60 billion.



Source

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
Health

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, on Sept. 17, 2020. Mike Blake | Reuters Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company raised its fiscal 2025 […]

Read More
Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval
Health

Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in […]

Read More
Eli Lilly earnings are coming Thursday. Here’s what top analysts expect
Health

Eli Lilly earnings are coming Thursday. Here’s what top analysts expect

Many on Wall Street expect that Novo Nordisk ‘s loss has been Eli Lilly ‘s gain, and this will be good news for the Zepbound maker’s second-quarter results. Novo Nordisk’s stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and […]

Read More